Research programme: antineoplastic antibodies - Monopar Therapeutics

Drug Profile

Research programme: antineoplastic antibodies - Monopar Therapeutics

Alternative Names: ATN-658; huATN-658; HuATN-658 - Monopar Therapeutics; Humanised ATN-658

Latest Information Update: 19 Sep 2016

Price : $50

At a glance

  • Originator Attenuon LLC
  • Developer Monopar Therapeutics
  • Class Monoclonal antibodies
  • Mechanism of Action Urokinase plasminogen activator receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Haematological malignancies; Solid tumours

Most Recent Events

  • 23 Jan 2014 Preclinical development is ongoing in USA
  • 23 Feb 2009 Preclinical development is ongoing in USA
  • 08 Nov 2007 Data presented at the 19th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2007) added to the Cancer pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top